TGTX - TG Therapeutics, Inc.
| Previous Close | 8.14 |
| Open | 8.20 |
| Bid | 7.82 x 4000 |
| Ask | 7.83 x 800 |
| Day's Range | 7.50 - 8.20 |
| 52 Week Range | 3.32 - 16.00 |
| Volume | 2,003,113 |
| Avg. Volume | 2,413,091 |
| Market Cap | 641.08M |
| Beta (3Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.71 |
- Zacks•2 days ago
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
- Motley Fool•3 days ago
Is TG Therapeutics a Buy?
The stock price of this clinical-stage biotech has nearly doubled so far in 2019.
- Simply Wall St.•3 days ago
Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholder...
- GlobeNewswire•4 days ago
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
TG Therapeutics, Inc. (TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with all three types of marginal zone lymphoma (MZL): nodal, extranodal, and splenic MZL. The MZL cohort of the UNITY-NHL trial is currently evaluating the safety and efficacy of single agent umbralisib in patients with MZL who have received at least one prior anti-CD20 regimen, the same indication for which the FDA recently granted breakthrough therapy designation for umbralisib.
- GuruFocus.com•9 days ago
5 Oncology Companies That Are Set to Run
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.
- Motley Fool•11 days ago
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
- Investopedia•18 days ago
TG Therapeutics Breaks Out on Positive Umbralisib Data
TG Therapeutics shares moved sharply higher after positive clinical data, but traders will be watching these key levels ahead.
- Zacks•18 days ago
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
- GlobeNewswire•18 days ago
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) Responses were durable, with median duration.
- GlobeNewswire•21 days ago
TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that interim data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b pivotal trial to be presented at the upcoming American Association for Cancer Research (AACR) annual meeting has an updated embargo date and time of Monday, April 1, 2019 at 8:30am ET. At that time, the abstract will be available via the AACR meeting website at www.aacr.org, and the data which will be presented during an oral session later that day (details below) will be available on the Company’s website at www.tgtherapeutics.com/publications.cfm.
- GlobeNewswire•last month
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania. Final data from the core Phase 2 trial has been previously presented, most recently at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, TX. In addition to highlighting the final Phase 2 data, the AAN presentation plans to include data from the open label extension (OLE), a trial made available to any patient who completed the core Phase 2 trial allowing them to continue treatment with ublituximab.
- Zacks•last month
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•last month
TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
NEW YORK, March 11, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•last month
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated cancers and autoimmune diseases, today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial. Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "We are highly encouraged that based on the progression-free survival data accumulated to date, the UNITY-CLL DSMB determined that the study was not futile and supported continuation of the trial as planned.
- Simply Wall St.•last month
Those Who Purchased TG Therapeutics Shares A Year Ago Have A 57% Loss To Show For It
This month, we saw the TG Therapeutics, Inc. (NASDAQ:TGTX) up an impressive 62%. But that doesn't change the fact that the returns over the last year have been disappointing. Specifically,Read More...
- Motley Fool•2 months ago
This Is Why TG Therapeutics Stock Soared 65.9% in February
A string of positive news on drugs in development sparked investor excitement.
- Zacks•2 months ago
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
- GlobeNewswire•2 months ago
TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced approximately $85 million in equity and debt financing. The Company priced a public offering of its common stock for gross proceeds of approximately $25.2 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase $3.8 million of additional shares of common stock.
- Benzinga•2 months ago
The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
- TheStreet.com•2 months ago
3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'
This is a nice win for this razor and razor-blade concern and helped drive a 15% rally in T2 Biosystems on Thursday. This trial combined the use of TG Therapeutics' compounds TG-1101 and TGR-1202 and Imbruvica to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. After the bell Thursday, TG Therapeutics took advantage of the rally in the stock to initiate a raise of capital.
- Zacks•2 months ago
Why These Pharma ETFs Rallied on Thursday
A few pharma ETFs hit a one-month high on Feb 28. Why?
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the final results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data were presented yesterday at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting held in Dallas, TX. The data was previously presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting held in October of 2018.
- Motley Fool•2 months ago
Why TG Therapeutics Stock Skyrocketed 30.5% Today
Positive data from a cohort in a key trial ignited investor optimism.
- GlobeNewswire•2 months ago
TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. TG Therapeutics intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
